SIGNET-RING CELLS IN ADVANCED GASTRIC CANCER A Clinical, Pathological and Histochemical Study

2009 ◽  
Vol 95A (1-6) ◽  
pp. 225-231
Author(s):  
DONATELLA SANTINI ◽  
FLORIANO BAZZOCCHI ◽  
GUIDO MAZZOLENI ◽  
MONICA RICCI ◽  
GIULIANO VITI ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Histochemical Study ◽  
Signet Ring Cells ◽  
Signet Ring

scholarly journals Mutations in Epigenetic Regulation Genes in Gastric Cancer

Cancers ◽  
2021 ◽  
Vol 13 (18) ◽  
pp. 4586
Author(s):  
Marina V. Nemtsova ◽  
Alexey I. Kalinkin ◽  
Ekaterina B. Kuznetsova ◽  
Irina V. Bure ◽  
Ekaterina A. Alekseeva ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Chromatin Remodeling ◽  
Epigenetic Regulation ◽  
Somatic Mutations ◽  
Distant Metastases ◽  
Clinical Markers ◽  
Signet Ring Cells ◽  
Mutational Profiling ◽  
Signet Ring ◽  
Epigenetic Processes

We have performed mutational profiling of 25 genes involved in epigenetic processes on 135 gastric cancer (GC) samples. In total, we identified 79 somatic mutations in 49/135 (36%) samples. The minority (n = 8) of mutations was identified in DNA methylation/demethylation genes, while the majority (n = 41), in histone modifier genes, among which mutations were most commonly found in KMT2D and KMT2C. Somatic mutations in KMT2D, KMT2C, ARID1A and CHD7 were mutually exclusive (p = 0.038). Mutations in ARID1A were associated with distant metastases (p = 0.03). The overall survival of patients in the group with metastases and in the group with tumors with signet ring cells was significantly reduced in the presence of mutations in epigenetic regulation genes (p = 0.036 and p = 0.041, respectively). Separately, somatic mutations in chromatin remodeling genes correlate with low survival rate of patients without distant metastasis (p = 0.045) and in the presence of signet ring cells (p = 0.0014). Our results suggest that mutations in epigenetic regulation genes may be valuable clinical markers and deserve further exploration in independent cohorts.

scholarly journals Polyserositis revealing a signet ring cells gastric adenocarcinoma in a 27 years old male patient: A case report.

2021 ◽  
Author(s):  
Zahid Talibi Alaoui ◽  
Salah Eddine Youbi ◽  
Fatima Ihbibane ◽  
Hind Rachidi ◽  
Fatima Ezzahra Hazmiri ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Emergency Department ◽  
Case Report ◽  
Clinical Improvement ◽  
Gastric Adenocarcinoma ◽  
Male Patient ◽  
Signet Ring Cells ◽  
Signet Ring

Abstract Gastric cancer remains one of the most common and deadly cancers worldwide, especially among old males. It is rare in the younger population (< 30 years old). We describe the case of a 27 years old male patient, presenting to the emergency department, with exsudative polyserositis, initially misdiagnosed and treated as a multifocal tuberculosis with no clinical improvement, later revealing a metastatic signet ring cells gastric adenocarcinoma.

Apatinib in the treatment of non-operable or advanced gastric cancer: Evidence of efficacy and safety in a real-world study.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15515-e15515
Author(s):  
Ligang Xing ◽  
Wei Cao ◽  
Gang Cui ◽  
Huanhu Zhang ◽  
Yiran Shi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cell Carcinoma ◽  
Advanced Gastric Cancer ◽  
Signet Ring Cell Carcinoma ◽  
Signet Ring Cell ◽  
Combined Chemotherapy ◽  
Efficacy And Safety ◽  
Signet Ring ◽  
Organ Metastasis ◽  
Ring Cell

e15515 Background: Apatinib, a small molecule tyrosine kinase inhibitor, has been approved to use in patients with advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma after at least two systemic chemotherapy regimens in China. This study aims to observe the efficacy and safety of apatinib in real word clinical practice and preliminarily explore the characteristics of population with more clinical benefit. Methods: This study included patients with non-operative or advanced gastric cancer confirmed by histopathology or cytology, and did not intervene the regimen which was entirely determined by the clinicians and patients. Results: From April 16, 2018 to January 12, 2019, 732 patients enrolled, and all patients had been followed up at least once. Total 342 patients were eligible for efficacy evaluation. Among them, 43 patients achieved partial response (PR), 209 patients achieved stable disease (SD) and 90 patients experienced progression disease (PD). The overall response rate (ORR) was 12.55%, and the disease control rate was 73.6%. The mPFS have not yet reached. For patients ≥65 years, the ORR was 26.32%, and for patients < 65 years, ORR was 8.33%. For patients with non-signet ring cell carcinoma and signet ring cell carcinoma, the ORRs were 15.22% and 6.0%. For patients with and without organ metastasis, the ORRs were 15.25% and 3.75% respectively. The PFS analysis showed that, Combined chemotherapy and age > 65 may predict longer PFS. The OS analysis showed that, ECOG 0-1, combined chemotherapy, AFP positive and male predict longer OS. The overall incidence of adverse events was 84%. The most common adverse events were hypertension (28.8%), fatigue (22.4%), hand-foot syndrome (17.3%), anorexia (12.8%) and nausea (10.5%). Conclusions: Apatinib showed promising antitumor activity in patients with non- operable or advanced Gastric Cancer in this real word study. The prolonging survival benefits maybe could be attenuated by age <65, without organ metastasis, ECOG score >1, treatment regimen, normal AFP, and pathological diagnosis of non-signet ring cell carcinoma. Clinical trial information: ChiCTR1800015701.

scholarly journals Clinicopathological differences in signet ring cell adenocarcinoma between early and advanced gastric cancer

2018 ◽  
Vol 22 (2) ◽  
pp. 255-263 ◽  
Author(s):  
Yi-Chu Kao ◽  
Wen-Liang Fang ◽  
Ruei-Fang Wang ◽  
Anna Fen-Yau Li ◽  
Muh-Hwa Yang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Signet Ring Cell ◽  
Signet Ring Cell Adenocarcinoma ◽  
Signet Ring ◽  
Ring Cell

Capcitabine and oxaliplatin (XELOX) in the treatment of advanced gastric cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14089-14089
Author(s):  
R. Quek ◽  
W. T. Lim ◽  
K. F. Foo ◽  
W. H. Koo ◽  
H. C. Toh
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Overall Response Rate ◽  
Venous Catheter ◽  
Toxicity Assessment ◽  
Signet Ring Cell ◽  
Signet Ring ◽  
Measurable Disease ◽  
Ring Cell ◽  
Grade 3

14089 Background: Effective 1st line chemotherapy that is easily delivered and tolerable is important in patients with advanced gastric cancer (AGC). This study aimed to evaluate the toxicity and efficacy of combination capecitabine and oxaliplatin (XELOX), given 3 weekly, in patients with AGC. Methods: Twenty-seven patients with AGC, were treated with XELOX at the National Cancer Centre Singapore between June 2003 and December 2005. Capecitabine was given 2000 mg/m2/day, days 1–14, and oxaliplatin was given 130 mg/m2 on day 1, every 21 days. Results: The median age was 61 years with 22% of patients ≥ 70 years. One-third of patients had ECOG 2 - 4, and 33% of patients had signet ring cell histology. Median doses of capecitabine and oxaliplatin achieved were 1500 mg/m2/day (1200 - 2400) and 130mg/m2 (80 - 130) respectively. A median of 5 cycles (range 1 - 8) of XELOX was administered. All 27 patients had toxicity assessment. Toxicities were infrequent and mild. There were 3 cases of grade 3/4 toxicities (thrombocytopenia, neutropenia and fatigue). Twenty-two patients had measurable disease for response evaluation. Complete (CR) and partial (PR) response rates were 9 and 50% respectively. Overall response rate was 59%. Chemo-naïve patients had better responses (80% vs 25%). Four of the remaining 5 patients had reduction in non-measurable disease or in tumor marker levels. Of the 9 patients with ECOG > 1, there was radiological CR in 1 patient and 5 PR; 1 had normalization of CEA, another reversal of disseminated intravascular coagulation and the third decreased ascites. The median time to progression and overall survival were 5.9 months and 7.6 months respectively. Conclusions: XELOX regimen is safe, active and well tolerated in AGC even in patients with poor ECOG status. It is easily administered without requiring a central venous catheter. This regimen should be investigated further in a prospective manner. No significant financial relationships to disclose.

scholarly journals Krukenberg's Tumor as an Incidental Finding in a Full-Term Pregnancy: A Case Report

2020 ◽  
Author(s):  
Orlando Andres Nunez-Isaac ◽  
Felipe Mendoza-Rosado ◽  
Katheryn Lopez-Arjona ◽  
Alan Espinosa-Marron ◽  
Fernando Davila-Martinez
Keyword(s):  
Gastric Cancer ◽  
Pregnant Woman ◽  
Incidental Finding ◽  
Abdominal Cavity ◽  
Vena Cava ◽  
Krukenberg Tumor ◽  
Mri Findings ◽  
Signet Ring Cells ◽  
Uncommon Presentation ◽  
Signet Ring

BACKGROUND Krukenberg tumor is a rare metastatic tumor of the ovary with characteristic histopathological features known as signet-ring cells. It usually presents in women around 45 years of age, however, we present an uncommon case in a 38-year-old pregnant woman. We report this case because of the unusual findings, the uncommon presentation in this younger age bracket, its diagnostic challenge, and poor prognosis. CASE PRESENTATION We describe an unusual case of a young woman with a history of painful vaginal bleeding at 13 weeks of pregnancy and treated for abruptio placentae. In her routine prenatal visit at week 20 of pregnancy, she was found to have a uterine fundus greater than her gestational age and referred to the hospital to discard polyhydramnios. At her admission a pelvic ultrasound was performed with normal findings of a 25 weeks pregnancy, also showing bilateral enlarged ovaries with heterogeneous echogenicity. The MRI showed a left tumoral lesion with dimensions of 22.1 x 13.6 x 16.3 cm, with lobulated regular contours with displacement of peripheral structures and mild compression of the bladder, the left ureter, and the inferior vena cava. The lesion was heterogeneous with irregular borders. The patient was programmed for a cesarean section; during the operation, the abdominal cavity showed bilateral tumors compatible with MRI findings, the ovarian tumors were sent to pathology and the results showed poorly differentiated mucinous adenocarcinoma (WHO III) with extensive signet-ring cells, an indicative of Krukenberg tumor. CONCLUSION: The case presented is rare due to its presentation in a pregnant woman without identifiable risk factors for gastric cancer. The incidental finding suggests the pregnancy masked the clinical presentation of gastric cancer, and the rapid deterioration of the patient is consistent with the aggressiveness described in the literature. The limited descriptions of this neoplasm in our country and the torpid evolution of this case highlight the importance of further studies of this cancer in Mexico.

scholarly journals Chemoradiotherapy Is Inferior to Chemotherapy Alone in Adjuvant Setting for Signet Ring Cell Containing Gastric Cancer

2020 ◽  
Vol 10 ◽  
Author(s):  
Yue-Ting Zhu ◽  
Xin-Zu Chen ◽  
Ye Chen ◽  
Yu-Wen Zhou ◽  
Lian-Sha Tang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Adjuvant Chemotherapy ◽  
Signet Ring Cell ◽  
Adjuvant Chemoradiotherapy ◽  
Signet Ring Cells ◽  
D2 Gastrectomy ◽  
Vessel Invasion ◽  
Signet Ring ◽  
Ring Cell

BackgroundSignet ring cell containing gastric cancer (SRCGC) is a rare subtype of gastric cancer, and its adjuvant therapy is based on general gastric cancer. However, the effectiveness of radiotherapy for those SRCGC patients remains unknown.PurposeThe purpose of the study was to analyze whether the addition of radiotherapy to adjuvant chemotherapy (CT) can benefit survival in resected SRCGC patients.MethodsPatients with SRCGC, who underwent D2 gastrectomy followed by adjuvant chemotherapy or chemoradiotherapy (CRT), were retrospectively collected. According to the proportion of signet ring cells, patients were histologically classified as pure SRCGC (pSRCGC) containing 100% of signet ring cells, mixed SRCGC (mSRCGC) containing &gt;50% of signet ring cells, and contaminated SRCGC (cSRCGC) containing &lt;50% of signet ring cells. Among the 272 patients, 156 were treated by CT alone and 116 by CRT. The primary endpoint was 3-year overall survival rate (3-year OS rate).ResultsWith a median follow-up of 80.5 months, the 3-year OS rate was significantly higher in the CT group (70.5% vs. 58.6%, HR = 0.633, P = 0.017) compared with CRT group. Three independent characteristics were predictive of a poor overall survival: CRT treatment (P = 0.019), tumor size ≥5 cm (P &lt; 0.001), and the presence of vessel invasion (P = 0.009). Subgroup analyses showed CRT significantly impaired prognosis in SRCGC patients in the cSRCGC subset, as well as lesions located in lower-middle sites, subtotal gastrectomy, male, &lt;60 year, and no vessel invasion. Peritoneal was the most common recurrence site in SRCGC patients. The adverse events leukopenia and neutropenia were more common in the CRT group (P = 0.007).ConclusionsAdjuvant chemoradiotherapy was associated with poor survival compared with adjuvant chemotherapy in SRCGC patients with D2 gastrectomy.

Sign in / Sign up

Export Citation Format

Share Document